DNA X delays quarterly filing over preferred stock accounting
SONM•DNA X delayed its Form 10-Q for the quarter ended September 30, 2026, while reviewing the accounting for related-party preferred stock issuances. It expects to file within five calendar days of the due date and estimates a continuing-operations net loss of about $1.3 million, compared with $2.2 million a year earlier.
1. Filing delay
DNA X delayed its Form 10-Q for the three months ended September 30, 2026, as a review of related-party preferred stock accounting prolonged its financial close. The review concerns whether the stock should be classified as mezzanine equity or permanent equity; the company expects to file within five calendar days of the prescribed due date.
2. Expected loss
The company expects a net loss from continuing operations of approximately $1.3 million, down from approximately $2.2 million in the corresponding 2025 period. The narrower loss reflects $500,000 in prior-year interest expense on promissory notes repaid in January 2026 and $400,000 in prior-year divestiture-related legal fees.




